Bristol Myers Squibb (BMY) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$63.73

Open

$64.07

Day range

$63.22 – $64.38

Volume

9.4M

About Bristol Myers Squibb

Latest BMY news

• Triad experts weigh in on the Canadian and US trade war and how it could affect pharmaceuticals
  Geopolitics · Sep 11, 2026

  The ongoing trade tensions between Canada and the United States are raising concerns among industry experts regarding their potential impact on the pharmaceutical sector. As both nations grapple with tariffs and regulatory barriers, the implications for drug pricing, supply chains, and research collaboration are becoming increasingly pronounced. Experts warn that heightened trade disputes could lead to increased costs for pharmaceutical companies, which may ultimately be passed on to consumers in the form of higher drug prices. Moreover, the trade war could disrupt the intricate supply chains that underpin the pharmaceutical industry. Canada is a significant player in the production of active pharmaceutical ingredients (APIs) and generic drugs, and any restrictions on trade could hinder the availability of these essential components in the U.S. market. This disruption could lead to shortages and delays in drug production, further complicating the already challenging landscape of healthcare delivery. In light of these developments, pharmaceutical companies may need to reassess their strategies, potentially shifting production locations or increasing domestic sourcing to mitigate risks associated with trade volatility. Investors should remain vigilant, as the evolving trade dynamics could influence stock valuations within the sector, particularly for companies heavily reliant on cross-border trade. As the situation unfolds, the pharmaceutical industry will be closely monitoring policy changes and seeking ways to adapt to the shifting trade landscape.

• The benefits of next-generation peptides will be thinly spread
  FT Companies · Sep 9, 2026

  Next-generation peptides, which have garnered attention for their potential in various therapeutic applications, are likely to face challenges in widespread adoption due to their cost and consumer price sensitivity. A recent survey indicates that pricing is a significant factor influencing consumer decisions, with many opting to discontinue use when faced with rising costs. This trend suggests that while the scientific advancements in peptide technology may be promising, their market penetration could be limited if manufacturers do not address affordability. The implications for the peptide market are considerable. As companies strive to innovate and differentiate their products, they may need to balance the costs of research and development with the price points that consumers are willing to accept. If manufacturers cannot find a way to produce these next-generation peptides at a lower cost, the benefits of their advancements may be "thinly spread" across a limited consumer base. This could lead to a fragmented market where only a few players succeed, while others struggle to maintain profitability in a price-sensitive environment. Investors and stakeholders should monitor how pricing strategies evolve in response to consumer behavior, as this will be crucial for the future of peptide therapeutics.

• Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
  MarketWatch · Sep 8, 2026

  Shares of Novartis plummeted over 3% on Monday following the disappointing results of a pivotal trial for its cholesterol drug, which aimed to lower lipoprotein(a) or Lp(a) levels to reduce cardiovascular risks. The failure of this trial not only undermines Novartis's strategy but also raises concerns about the broader viability of Lp(a) targeting therapies in the biopharmaceutical sector. Investors had anticipated significant advancements in this area, making the trial results particularly impactful. The fallout from Novartis's announcement extended beyond its own stock, triggering a selloff across the biopharma industry as market participants reevaluated the potential of similar treatments from other companies. The collective market response reflects a growing skepticism towards the efficacy of Lp(a) lowering strategies, which had garnered considerable attention and investment. Analysts suggest that this could lead to a reevaluation of research and development priorities within the sector, as companies may now face increased pressure to demonstrate the viability of their cardiovascular drug pipelines.

• Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch
  Market Outlook · Sep 7, 2026

  The ulcerative colitis market is poised for significant growth, with projections estimating its value to reach USD 15.99 billion by 2033, up from USD 10.16 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.7%. This expansion is largely driven by the increasing prevalence of the disease and the ongoing development of innovative therapies. Currently, the market is dominated by anti-TNF therapies, but a new wave of late-stage drug candidates is set to reshape treatment paradigms. Among the five late-stage drug candidates to watch are promising therapies that target various mechanisms of action, including integrins and JAK inhibitors. These candidates are expected to offer improved efficacy and safety profiles compared to existing treatments, which primarily include 5-aminosalicylic acid (5-ASA) therapies and corticosteroids. As these new therapies progress through Phase 3 and Phase 4 trials, their potential market entry could lead to increased competition and a shift in treatment strategies for patients with moderate to severe ulcerative colitis. The anticipated launch of these late-stage candidates is likely to impact market dynamics significantly, as healthcare providers and patients seek more effective and targeted treatment options. As the landscape evolves, pharmaceutical companies are expected to invest heavily in research and development to capitalize on the growing demand for ulcerative colitis therapies, ultimately enhancing patient outcomes and driving market growth.

• Pharma stocks soar as investors seek AI alternatives
  FT Companies · Aug 30, 2026

  Pharmaceutical stocks have experienced a significant surge in recent months, with many companies reaching record highs in August. This upward trend is largely attributed to a strategic shift among investors who are increasingly looking for alternatives to the volatile artificial intelligence sector. The positive momentum in the pharma industry has been further fueled by promising clinical trial results, which have instilled confidence in the potential for new drug approvals and market expansions. As investors pivot towards pharmaceuticals, the sector has become a beacon of stability amid broader market fluctuations. Analysts suggest that the robust performance of drugmakers could be indicative of a longer-term trend, as the demand for innovative therapies continues to grow. This shift not only reflects a desire for diversification but also highlights the resilience of the healthcare sector in times of economic uncertainty. With ongoing advancements in biotechnology and increased investment in research and development, pharmaceutical companies are well-positioned to capitalize on this renewed interest, potentially leading to sustained growth in stock valuations.

• FAQ: The Strategic and Regulatory Logic Behind Biopharma M&A, From Deal Pricing to IND Sponsorship
  IPO & M&A · Aug 26, 2026

  The biopharmaceutical sector has witnessed a surge in mergers and acquisitions (M&A) activity, driven by a combination of strategic imperatives and regulatory considerations. Companies are increasingly looking to consolidate their portfolios to enhance research capabilities, expand market access, and accelerate the development of innovative therapies. Deal pricing has become a critical factor, with valuations often reflecting not only the current pipeline potential but also the anticipated regulatory hurdles and market dynamics. Regulatory frameworks play a significant role in shaping M&A strategies within the biopharma industry. The process of Investigational New Drug (IND) sponsorship is a key consideration for companies evaluating potential acquisitions. Firms are keenly aware that the ability to navigate the complex regulatory landscape can significantly impact the success of drug development and commercialization. As a result, acquiring companies often seek targets with established regulatory pathways or promising candidates that align with their strategic goals. Market implications of these trends are profound. Increased consolidation can lead to reduced competition, potentially impacting drug pricing and availability. Conversely, successful mergers can result in enhanced innovation, as combined resources may lead to more robust R&D efforts. Investors are closely monitoring these developments, as the outcomes of biopharma M&A activity will likely influence stock valuations and the overall health of the sector in the coming years.

• Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - 24/7 Wall St.
  IPO & M&A · Aug 20, 2026

  Seaport Therapeutics has successfully completed its initial public offering (IPO), drawing significant interest from major pharmaceutical players such as Bristol Myers Squibb and Johnson & Johnson. The company’s innovative prodrug platform, which aims to enhance the efficacy and safety of existing therapies, has positioned it as a potential disruptor in the biopharmaceutical landscape. This IPO not only marks a pivotal moment for Seaport but also highlights the growing trend of established firms looking to invest in cutting-edge biotech innovations. The attention from industry giants suggests that Seaport's technology could complement or enhance existing drug portfolios, potentially leading to strategic partnerships or acquisitions in the near future. Investors are keenly observing how this development may influence market dynamics, particularly in the oncology and immunology sectors where both Bristol Myers and Johnson & Johnson have substantial stakes. As these companies seek to bolster their pipelines, Seaport's performance post-IPO could significantly impact their stock valuations and investment strategies moving forward.

• Trump calls his new FDA pick ‘Dr. Heidi.’ Patty Murray calls her a ‘far-right, anti-abortion extremist’
  Fortune · Aug 20, 2026

  Former President Donald Trump has announced his selection of Dr. Heidi Steltzer as his nominee for the Food and Drug Administration (FDA) commissioner, a move that has sparked significant controversy. Steltzer, a physician with a background in women's health, has been labeled by Senate Health, Education, Labor and Pensions Committee Chair Patty Murray as a "far-right, anti-abortion extremist." This characterization raises concerns about the potential direction of the FDA under her leadership, particularly regarding reproductive health policies and drug approvals related to women's health. The nomination comes at a time when the FDA is under scrutiny for its handling of various health issues, including the approval of abortion medications and the regulation of reproductive health services. Market analysts are closely watching how this nomination could influence pharmaceutical stocks, especially those involved in reproductive health products. If Steltzer's confirmation leads to stricter regulations or a shift in focus away from reproductive health, companies in this sector may face increased volatility. Conversely, if her appointment signals a more lenient approach towards drug approvals, it could bolster investor confidence in the pharmaceutical industry. As the nomination process unfolds, it is likely to ignite further political debate, potentially impacting broader market sentiment. Investors will be keen to assess how this appointment aligns with the current administration's health policies and the implications for public health initiatives, particularly in light of the ongoing discussions surrounding reproductive rights in the United States.

• Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates
  Market Outlook · Aug 19, 2026

  The checkpoint inhibitor refractory cancer market is poised for substantial growth by 2036, as biopharma companies continue to advance novel immuno-oncology candidates. Recent insights indicate that the landscape for treating cancers resistant to checkpoint inhibitors is evolving, with a focus on innovative therapies that can enhance patient outcomes. This shift is largely attributed to the increasing understanding of tumor microenvironments and the mechanisms behind immune evasion. As the market expands, the introduction of new therapeutic agents is expected to address the limitations of existing checkpoint inhibitors, which have shown efficacy in only a subset of patients. The development pipeline includes a variety of promising candidates, such as combination therapies and next-generation immune modulators, which aim to improve response rates and prolong survival in refractory cases. This evolution not only reflects the growing investment in cancer research but also signals potential shifts in treatment paradigms that could benefit patients who have exhausted current options. Market implications are significant, as the anticipated growth in this sector may attract increased investment from both established pharmaceutical companies and emerging biotech firms. The success of these novel therapies could lead to a revaluation of existing treatment protocols and potentially reshape the competitive landscape in oncology. As biopharma companies continue to innovate, stakeholders will closely monitor clinical trial outcomes and regulatory approvals that could further influence market dynamics in the coming years.

• The Key to Pharma M&A: Never Shopping Hungry
  IPO & M&A · Aug 19, 2026

  In the competitive landscape of the pharmaceutical industry, executives are under constant pressure to replenish their pipelines, especially as blockbuster drugs face patent expirations. This urgency can lead to hasty mergers and acquisitions (M&A) decisions, which, as industry experts caution, can result in costly missteps. The adage "never shop hungry" resonates strongly in this context, emphasizing the need for strategic foresight rather than impulsive buying. Pharmaceutical companies are advised to approach M&A with a clear strategy, focusing on long-term value rather than immediate needs. The recent trend of aggressive acquisitions has raised concerns among analysts about inflated valuations and integration challenges. Companies that prioritize thorough due diligence and align acquisitions with their core competencies are more likely to achieve successful outcomes. As the market adjusts to these dynamics, investors are increasingly scrutinizing M&A activities, seeking assurance that companies are not merely reacting to short-term pressures but are instead making calculated investments that will sustain growth and innovation in the long run.

All 32 articles in the app →

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen